Related Experiment Video
Updated: Jul 8, 2025
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
Synthesis of melampomagnolide B derivatives as potential anti-Triple Negative Breast Cancer agents
Tianyang Chen1, Xiaoping Chen1, Lingling Liu1
1State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin, 300350, People's Republic of China.
Abstract:
Triple-negative breast cancer (TNBC) is the most malignant and aggressive subtype of breast cancer. Currently, the treatment options to TNBC are limited and the discovery of new drugs and novel therapeutic strategies for treatment of TNBC is urgently needed. In this study, a series of melampomagnolide B (MMB) derivatives were designed, synthesized, and evaluated for their anti-TNBC activities. Compound 7 and 13a showed highly potent activity against different TNBC cells with IC50 values ranging from 0.37 μM to 1.52 μM, which demonstrated 3.6- to 54-fold improvement comparing to the parent compound MMB. The phenotypic effect revealed that compound 7 and 13a could inhibit metastasis, induce apoptosis and arrest cell cycle distribution of TNBC cells. Furthermore, the mechanism research indicated compounds 7 and 13a bound IKKβ and inhibited the IKKβ-mediated phosphorylation of IκB and p65, then inhibited the nuclear translocation of p65 and eventually regulated the genes related to metastasis, apoptosis and cell cycle under NF-κB control. Moreover, compound 7 inhibited the tumor growth in vivo, and the weights of spleens and livers were also reduced compared with control group which indicated that compound 7 could inhibit metastasis of TNBC in vivo. These findings indicate that compound 7 may be used as a promising lead compound for ultimate discovery of anti-TNBC drug.
Insights
New melampomagnolide B derivatives show potent anti-triple-negative breast cancer (TNBC) activity. Compounds 7 and 13a effectively inhibit TNBC cell growth, metastasis, and induce apoptosis, offering promising therapeutic leads.
Area of Science:
- Medicinal Chemistry
- Oncology
- Molecular Biology
Background:
- Triple-negative breast cancer (TNBC) is an aggressive subtype with limited treatment options.
- There is an urgent need for novel therapeutic strategies and drugs for TNBC.
- Melampomagnolide B (MMB) serves as a structural basis for developing new anti-cancer agents.
Purpose of the Study:
- To design, synthesize, and evaluate novel melampomagnolide B derivatives for anti-TNBC activity.
- To investigate the mechanism of action of potent MMB derivatives in TNBC cells.
- To assess the in vivo efficacy of the most promising compound against TNBC.
Main Methods:
- Synthesis of a series of MMB derivatives.
- In vitro evaluation of anti-proliferative activity against TNBC cell lines (IC50 determination).
- Phenotypic assays (metastasis, apoptosis, cell cycle analysis) and mechanistic studies (protein binding, phosphorylation, nuclear translocation, gene regulation via NF-κB pathway).
- In vivo tumor growth inhibition and metastasis assessment in a TNBC mouse model.
Main Results:
- Compounds 7 and 13a exhibited significant anti-TNBC activity, with IC50 values significantly lower than the parent MMB.
- Phenotypic effects included inhibition of metastasis, induction of apoptosis, and cell cycle arrest.
- Mechanistic studies revealed that compounds 7 and 13a target IKKβ, inhibiting the NF-κB signaling pathway.
- Compound 7 demonstrated in vivo efficacy by inhibiting tumor growth and reducing spleen and liver weights, suggesting anti-metastatic effects.
Conclusions:
- Novel MMB derivatives, particularly compound 7, show potent anti-TNBC activity.
- The compounds exert their effects by inhibiting the IKKβ/NF-κB pathway, impacting metastasis, apoptosis, and cell cycle.
- Compound 7 is a promising lead compound for the development of new anti-TNBC drugs.
